StockNews.AI
CYTK
StockNews.AI
10 hrs

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

1. Cytokinetics to present MAPLE-HCM results at two key medical sessions. 2. Aficamten demonstrated effectiveness in hypertrophic cardiomyopathy treatments. 3. Upcoming presentations may enhance visibility for aficamten's potential and benefits. 4. Cytokinetics is preparing for regulatory approvals for aficamten. 5. The company's innovative drug pipeline positions it for future growth.

11m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical results for aficamten can lead to increased investor confidence and potential stock price appreciation, as seen historically with other pharmaceutical companies like Amgen following successful trial announcements.

How important is it?

The article provides insightful updates into clinical presentations for aficamten, crucial for investor interest and stock price implications directly affecting CYTK.

Why Short Term?

The upcoming presentations and discussions can catalyze immediate market reactions, similar to how initial trial results have influenced firms like Vertex Pharmaceuticals when they share trial updates.

Related Companies

AMGNVRTXALNY
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations related to MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on November 7, 2025, and at the American Heart Association Scientific Sessions 2025 taking place November 7-10, 2025, both in New Orleans, LA. Hypertrophic Cardiomyopathy Medical Society Scientific Sessions Late Breaking Science Presentation Title: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyPresenter: Michael E. Nassif, M.D., University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart InstituteDate: November 7, 2025Session Title: Featured Science: Hypertrophic Cardiomyopathy Medical SocietySession Time: 6:00 PM – 6:35 PM CTPresentation Time: 6:16 PM – 6:22 PM CTLocation: R01 Oral Presentation Title: Long-term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM Presenter: Shepard D. Weiner, M.D., Columbia University Irving Medical CenterDate: November 7, 2025Session Title: Hypertrophic Cardiomyopathy Medical Society Oral AbstractsSession Time: 2:40 PM – 3:30 PM CTPresentation Time: 2:50 PM – 2:58 PM CTLocation: R02-R03 Poster Presentation Title: Outcomes Following Septal Myectomy in Young Patients with Obstructive Hypertrophic CardiomyopathyPresenter: Daniel Kamna, D.O., Oregon Health & Science UniversityDate: November 7, 2025Session Title: Hypertrophic Cardiomyopathy Medical Society PostersSession Time: 6:30 PM – 7:30 PM CTLocation: R04-R05 Posters American Heart Association Scientific Sessions 2025 Late Breaking Science Presentations Title: Clinical Responses to Aficamten Monotherapy Compared with Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder AnalysisPresenter: Andrew Wang, M.D., Duke University Medical CenterDate: November 8, 2025Session Title: From Madrid to Mardi Gras: Heart Failure Trials on ParadeSession Time: 1:30 PM – 2:45 PM CTPresentation Time: 1:59 PM – 2:07 PM CTLocation: 211-213 Title: Effect of Aficamten versus Metoprolol Monotherapy on Biomarkers in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM TrialPresenter: Neal K. Lakdawala, M.D., Brigham and Women’s Hospital, Harvard Medical SchoolDate: November 9, 2025Session Title: Biological and Pragmatic Interventions in Heart Failure: From Present to FutureSession Time: 8:00 AM – 9:15 AM CTPresentation Time: 8:24 AM – 8:32 AM CTLocation: 211-213 Moderated Poster Presentations Title: Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM TrialPresenter: Henri Lu, M.D., Brigham and Women’s Hospital, Harvard Medical School Date: November 8, 2025Session Title: Beyond the Usual Suspects: Imaging Insights in HCM and Rare CardiomyopathiesSession Time: 9:15 AM – 10:30 AM CTPoster Presentation Time: 9:43 AM – 9:48 AM CTLocation: Clinical Science Zone 1, Moderated Digital Poster 7 Title: Aficamten is Safe and Effective in oHCM with Comorbidities Obesity, Hypertension, and Diabetes: a SEQUOIA-HCM Sub-studyPresenter: Matthew M. Y. Lee, Ph.D., MBChB, School of Cardiovascular and Metabolic Health, University of GlasgowDate: November 8, 2025Session Title: Targeting the Thickened Heart: Advances in Hypertrophic Cardiomyopathy TherapySession Time: 10:45 AM – 11:55 AM CTPoster Presentation Time: 11:13 AM – 11:18 AM CTLocation: Clinical Science Zone 2, Moderated Digital Poster 24 Title: Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic CardiomyopathyPresenter: Xiaowen Wang, M.D., MPH, Brigham and Women’s Hospital, Harvard Medical SchoolDate: November 8, 2025Session Title: Heart Failure and Cardiomyopathy: From Bench to BedsideSession Time: 3:15 PM – 4:25 PM CTPoster Presentation Time: 4:04 PM – 4:09 PM CTLocation: Clinical Science Zone 2, Moderated Digital Poster 22 Title: Chronic Aficamten Treatment Results in Sustained Favorable Cardiac Remodeling in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the FOREST-HCM TrialPresenter: Sheila M. Hegde, M.D., MPH, UT Southwestern Medical Center and Brigham and Women’s Hospital, Harvard Medical School Date: November 8, 2025Session Title: Imaging Insights from Multicenter Clinical Trials Session Time: 10:45 AM – 11:55 AM CTPoster Presentation Time: 10:45 AM – 10:50 AM CTLocation: Clinical Science Zone 1, Moderated Digital Poster 8 Title: Lactate Dehydrogenase and Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial Presenter: Ryohei Ono, M.D., Ph.D., British Heart Foundation Cardiovascular Research Centre, University of GlasgowDate: November 9, 2025Session Title: Drivers of Heart Failure: Environmental and Behavioral FactorsSession Time: 9:15 AM – 10:30 AM CTPoster Presentation Time: 10:04 AM – 10:09 AM CTLocation: Clinical Science Zone 2, Moderated Digital Poster 18 Poster Presentations Title: Semiquantitative Urine Dipstick Protein Assessments Predict Clinical Outcomes in Patients with Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF TrialPresenter: Ryohei Ono, M.D., Ph.D., British Heart Foundation Cardiovascular Research Centre, University of GlasgowDate: November 8, 2025Session Title: Biomarkers in HF: Past, Present, and FutureSession Time: 2:30 PM – 3:30 PM CTLocation: Clinical Science Zone 2 About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, an investigational cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function. For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube. Disclaimer Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of aficamten or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. Contact:Cytokinetics Diane WeiserSenior Vice President, Corporate Affairs(415) 290-7757

Related News